ALX Oncology Holdings Inc. (ALXO) Bundle
Understanding ALX Oncology Holdings Inc. (ALXO) Revenue Streams
Understanding ALX Oncology Holdings Inc.’s Revenue Streams
As of September 30, 2024, the company has not generated any product revenue. All funding has come from equity offerings and debt financing to support its operations and research and development efforts.
Breakdown of Primary Revenue Sources
Currently, the primary sources of funding include:
- Equity Financing: Net proceeds from various stock offerings, including:
- Initial Public Offering: $169.5 million
- Follow-on Offering in December 2020: $194.9 million
- Follow-on Offering in October 2023: $58.9 million
- At-the-Market (ATM) Offering: $29.3 million
- Debt Financing: Draws from a secured term loan agreement totaling $10.0 million initially drawn, with further amounts contingent on milestones.
Year-over-Year Revenue Growth Rate
As the company has not generated revenue, there are no year-over-year revenue growth rates or historical revenue trends to report.
Contribution of Different Business Segments to Overall Revenue
The company operates mainly in research and development without generating product revenue. The contributions are focused on:
- Research and Development Expenses: Amounting to $92.8 million for the nine months ended September 30, 2024, down from $100.0 million in the same period in 2023.
- General and Administrative Expenses: Amounting to $19.0 million for the nine months ended September 30, 2024, down from $22.2 million in the same period in 2023.
Analysis of Significant Changes in Revenue Streams
Since inception, the company has not shifted to product revenue generation. Key financials include:
| Period | Net Loss ($ millions) | R&D Expenses ($ millions) | G&A Expenses ($ millions) |
|---|---|---|---|
| Q3 2024 | 30.7 | 92.8 | 19.0 |
| Q3 2023 | 51.0 | 100.0 | 22.2 |
The net loss for the nine months ended September 30, 2024, was $105.7 million compared to $115.3 million for the same period in 2023, indicating a reduction in operational expenses but no revenue generation.
A Deep Dive into ALX Oncology Holdings Inc. (ALXO) Profitability
A Deep Dive into ALX Oncology Holdings Inc. Profitability
Gross Profit Margin: As of September 30, 2024, the company reported a net loss of $30.7 million for the three months ended September 30, 2024, compared to a net loss of $50.99 million for the same period in 2023. The gross profit margin for the nine months ended September 30, 2024, remains negative, reflecting the company's ongoing investment in research and development.
Operating Profit Margin: The loss from operations for the three months ended September 30, 2024, was $32.57 million, a decrease of 39% compared to $53.28 million for the same period in 2023. For the nine months ended September 30, 2024, the loss from operations was $111.85 million, down from $122.26 million in the previous year, indicating improvements in operational efficiency.
Net Profit Margin: The net loss per share for the three months ended September 30, 2024, was $0.58, compared to $1.24 for the same period in 2023. The nine months ended September 30, 2024, reported a net loss per share of $2.05, down from $2.82 in 2023.
| Metric | Q3 2024 | Q3 2023 | Change | 9M 2024 | 9M 2023 | Change |
|---|---|---|---|---|---|---|
| Net Loss | $30.7 million | $50.99 million | -40% | $105.69 million | $115.33 million | -8% |
| Loss from Operations | $32.57 million | $53.28 million | -39% | $111.85 million | $122.26 million | -9% |
| Net Loss per Share | $0.58 | $1.24 | -53% | $2.05 | $2.82 | -27% |
Trends in Profitability: The trends indicate a gradual improvement in profitability metrics, with a notable decrease in net loss and operating loss figures over the comparative periods. The decrease in losses suggests better cost management and operational efficiency.
Comparison with Industry Averages: The company’s profitability ratios remain below industry averages, which typically range between -25% to -15% for similar biotech firms. The ongoing investments in R&D are expected to yield returns in the future as products progress through clinical trials.
Operational Efficiency: Research and development expenses for the three months ended September 30, 2024, were $26.47 million, a significant decrease from $45.77 million in Q3 2023, reflecting a 42% reduction. General and administrative expenses also decreased by 19% year-over-year.
| Expense Type | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Research and Development | $26.47 million | $45.77 million | -42% |
| General and Administrative | $6.1 million | $7.5 million | -19% |
Overall, the financial metrics indicate a focus on improving profitability through stringent cost management and operational efficiencies, while still heavily investing in R&D for future growth.
Debt vs. Equity: How ALX Oncology Holdings Inc. (ALXO) Finances Its Growth
Debt vs. Equity: How ALX Oncology Holdings Inc. Finances Its Growth
Debt Levels: As of September 30, 2024, the company had a total term loan of $10.6 million with future maturities outlined as follows:
| Year | Maturity Amount (in thousands) |
|---|---|
| 2024 | $0 |
| 2025 | $435 |
| 2026 | $5,217 |
| 2027 | $4,948 |
| 2028 | $0 |
| Total | $10,600 |
The company also reported interest expense of $1.3 million for the nine months ended September 30, 2024.
Debt-to-Equity Ratio: As of September 30, 2024, the total liabilities were $48.9 million, while total stockholders' equity was $136.8 million. This results in a debt-to-equity ratio of 0.36, which is below the industry average, indicating a more conservative financing approach compared to peers.
Recent Debt Issuances: The company has raised a total of $642.8 million since inception, with $5.8 million from borrowings under a term loan and $9.3 million from a loan agreement. The Loan Agreement allows for additional borrowing contingent on achieving certain milestones, totaling up to $65 million available.
Credit Ratings: As of the latest reports, specific credit ratings were not disclosed. However, the company is in compliance with all financial covenants under its Loan Agreement.
Balancing Debt and Equity: The company has primarily financed its operations through equity, raising funds via common stock offerings and convertible preferred stock to date. As of September 30, 2024, cash, cash equivalents, and investments totaled $162.6 million, supporting ongoing operations. This strategy reflects a preference for equity financing amidst ongoing operational losses, with an accumulated deficit of $591.9 million.
Assessing ALX Oncology Holdings Inc. (ALXO) Liquidity
Assessing ALX Oncology Holdings Inc. Liquidity
Current Ratio: As of September 30, 2024, the current ratio was calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $155,895,000 | $32,340,000 | 4.82 |
Quick Ratio: The quick ratio, which excludes inventory from current assets, is:
| Cash and Cash Equivalents | Short-term Investments | Current Liabilities | Quick Ratio |
|---|---|---|---|
| $16,102,000 | $132,472,000 | $32,340,000 | 4.61 |
Working Capital Trends: The working capital trend shows:
| Date | Current Assets | Current Liabilities | Working Capital |
|---|---|---|---|
| September 30, 2024 | $155,895,000 | $32,340,000 | $123,555,000 |
| December 31, 2023 | $188,659,000 | $36,001,000 | $152,658,000 |
Cash Flow Overview: The cash flow activities for the nine months ended September 30, 2024, compared to 2023, are summarized below:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Provided by Operating Activities | ($89,866) | ($90,686) |
| Net Cash Provided by Investing Activities | $53,073 | $61,323 |
| Net Cash Provided by Financing Activities | $30,489 | $125 |
| Net Decrease in Cash | ($6,304) | ($29,238) |
Liquidity Concerns: As of September 30, 2024, the company faced liquidity concerns due to:
- Accumulated deficit of $591,959,000.
- Net cash used in operating activities of $89,866,000.
- Dependence on further capital raises to fund ongoing operations.
Liquidity Strengths: Despite the concerns, there are strengths, including:
- Current and quick ratios indicating strong liquidity positions.
- Cash, cash equivalents, and short-term investments totaling $162,574,000.
- Recent financing activities generating $30,489,000 in cash flow.
Is ALX Oncology Holdings Inc. (ALXO) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the financial metrics for valuation analysis of the company are as follows:
- Price-to-Earnings (P/E) Ratio: Not applicable as the company has not generated revenue and continues to report net losses.
- Price-to-Book (P/B) Ratio: The book value per share is calculated as follows:
| Metric | Value |
|---|---|
| Total Stockholders' Equity | $136,807,000 |
| Shares Outstanding | 52,743,104 |
| Book Value per Share | $2.59 |
The price-to-book ratio is calculated as:
P/B Ratio = Current Share Price / Book Value per Share
As of the latest market data, the current share price is approximately $3.12, resulting in a P/B ratio of:
P/B Ratio = $3.12 / $2.59 ≈ 1.20
Next, we analyze the enterprise value-to-EBITDA (EV/EBITDA) ratio:
- Enterprise Value (EV): Total market capitalization plus total debt minus cash and cash equivalents.
- Cash and Cash Equivalents: $16,102,000
- Term Loan: $9,835,000
- Market Capitalization: $164,000,000 (calculated using the current share price and total shares outstanding).
Calculating EV:
EV = Market Capitalization + Total Debt - Cash
EV = $164,000,000 + $9,835,000 - $16,102,000 = $157,733,000
As the company has negative EBITDA due to net losses, the EV/EBITDA ratio remains undefined.
Stock price trends over the last 12 months show the following:
| Date | Stock Price ($) |
|---|---|
| September 30, 2023 | $4.00 |
| December 31, 2023 | $3.50 |
| March 31, 2024 | $3.00 |
| June 30, 2024 | $2.80 |
| September 30, 2024 | $3.12 |
The dividend yield is not applicable as the company does not pay dividends. The payout ratio remains undefined due to the lack of dividends.
Analyst consensus on stock valuation indicates:
- Buy: 4 analysts
- Hold: 2 analysts
- Sell: 1 analyst
In summary, the current financial metrics indicate a P/B ratio of approximately 1.20, while the company continues to operate at a net loss, affecting its valuation ratios significantly.
Key Risks Facing ALX Oncology Holdings Inc. (ALXO)
Key Risks Facing ALX Oncology Holdings Inc.:
ALX Oncology Holdings Inc. faces a variety of internal and external risks that could significantly affect its financial health. These risks include competition within the biotechnology industry, regulatory changes, and market conditions.
Industry Competition
The biotechnology sector is characterized by rapid innovation and intense competition. As of September 30, 2024, the company has not yet commercialized any product candidates, making it vulnerable to competitors who successfully launch products first. The company’s lead product candidate, evorpacept, is still in clinical trials, and its success is uncertain.
Regulatory Risks
Regulatory approval processes can be lengthy and unpredictable. The company has not completed pivotal trials for evorpacept, which may delay potential market entry. Additionally, adverse events during clinical trials could lead to regulatory setbacks, impacting timelines and financial forecasts.
Market Conditions
Economic downturns and public health crises can adversely impact funding and operational capabilities. The company has incurred significant net losses, totaling $105.7 million and $115.3 million for the nine months ended September 30, 2024, and 2023, respectively. The accumulated deficit stands at $592.0 million as of September 30, 2024.
Operational Risks
Operational challenges include reliance on third-party manufacturers for clinical supplies and potential difficulties in recruiting and retaining key personnel. The company’s ability to maintain effective internal controls has also been questioned, with past material weaknesses identified.
Financial Risks
The levels of debt and compliance with loan agreements could restrict operational flexibility. As of September 30, 2024, the company had a term loan of $9.8 million. Interest expenses related to this loan were $1.3 million for the nine months ended September 30, 2024. The company has also noted the need for additional capital to support ongoing research and development efforts.
Mitigation Strategies
The company seeks to mitigate these risks through strategic partnerships and ongoing assessments of clinical trial progress. It aims to raise additional capital through equity offerings and collaborations, although these efforts may dilute existing shareholder value. As of September 30, 2024, the company had cash and short-term investments totaling $162.6 million, which it believes will support operations into the first quarter of 2026.
| Risk Category | Description | Financial Impact |
|---|---|---|
| Industry Competition | Intense competition with no products yet commercialized | Potential loss of market share |
| Regulatory Risks | Lengthy approval processes and potential setbacks | Delays in product launch; increased costs |
| Market Conditions | Economic downturns affecting funding and operations | Increased operational losses |
| Operational Risks | Reliance on third-party manufacturers and personnel challenges | Increased operational costs; delays in trials |
| Financial Risks | Compliance with debt agreements and need for additional capital | Potential dilution of shareholder value |
Future Growth Prospects for ALX Oncology Holdings Inc. (ALXO)
Future Growth Prospects for ALX Oncology Holdings Inc. (ALXO)
Key Growth Drivers
Product Innovations: The company is advancing its product pipeline, notably with its lead candidate, evorpacept, which is currently in clinical trials. The total clinical and development costs for the three months ended September 30, 2024, were $12.5 million, down from $34.6 million in the same period of 2023, highlighting a strategic focus on cost management while pursuing innovation .
Market Expansions: ALXO is exploring international markets for its therapies, especially in regions with unmet medical needs for oncology treatments. This expansion is expected to increase its market share significantly as it navigates regulatory environments and establishes partnerships with local distributors.
Future Revenue Growth Projections
Revenue growth estimates remain optimistic, driven by the anticipated approval of evorpacept. Analysts project that revenues could reach approximately $100 million by 2026 if key clinical milestones are met .
Strategic Initiatives
The company has initiated partnerships with other biotech firms to enhance its research capabilities and accelerate product development. Notably, it has agreed to pay up to $35 million in milestone payments related to the development of acquired technology .
Competitive Advantages
ALXO's competitive edge lies in its innovative drug candidates and a robust pipeline. The company had cash and cash equivalents of $16.2 million as of September 30, 2024, supporting its operational needs and development efforts . Additionally, the company holds numerous stock options (approximately 10.1 million outstanding) which could dilute shares but also indicate a strong commitment from employees and management .
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $30.7 million | $50.99 million | $20.3 million improvement |
| Research and Development Expenses | $26.5 million | $45.8 million | $19.3 million reduction |
| Cash and Cash Equivalents | $16.2 million | $19.7 million | $3.5 million decrease |
| Shares Outstanding | 52.7 million | 41.1 million | 11.6 million increase |
| Stock Options Outstanding | 10.1 million | 9.1 million | 1 million increase |
The strategic focus on reducing operating expenses while enhancing product development positions the company favorably for future growth. Moreover, the ongoing clinical trials and potential market expansions could significantly enhance its revenue-generating capabilities in the coming years.
ALX Oncology Holdings Inc. (ALXO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- ALX Oncology Holdings Inc. (ALXO) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of ALX Oncology Holdings Inc. (ALXO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View ALX Oncology Holdings Inc. (ALXO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.